Education
About Us
Working with TipRanks
Follow Us
Novabay Pharmaceuticals (NBY)
:NBY
NBY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.36 - $9.11
Previous CloseN/A
Volume41.84K
Average Volume (3M)59.88K
Market Cap
$2.91M
Enterprise Value$4.18M
Total Cash (Recent Filing)$12.89M
Total Debt (Recent Filing)$372.00K
Price to Earnings (P/E)―
Beta1.42
Next Earnings
May 08, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.16
Shares Outstanding5,816,204
10 Day Avg. Volume83,002
30 Day Avg. Volume59,875
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.28
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market Cap1.44
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.53
Enterprise Value/Ebitda-0.72
Forecast
1Y Price Target
$0.85Price Target Upside73.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
NovaBay Pharma News
PremiumCompany Announcements
NovaBay Pharmaceuticals Delays Yearly Report Filing
PremiumPre-Earnings
Is NBY a Buy, Before Earnings?
PremiumCompany Announcements
NovaBay Pharma’s Strategic Shift and Liquidation Plans
PremiumCompany Announcements
NovaBay Pharmaceuticals Reports Q3 2024 Financials Amid Strategic Changes
---
Bulls Say, Bears Say
Bulls Say
Asset SaleNovaBay accepted an increased offer of $11.5 million for its Avenova assets, which may benefit the company's financial position.
Business StrategyThe sale of DERMAdoctor should reduce its cash burn and allows it to focus on pursuing newer and stronger growth opportunities that are better aligned with its core eyecare business.
Bears Say
Financial PerformanceNet loss was $1.6 million or EPS of $(1.37) compared with our estimates of $(1.28) and consensus of $(1.23).
Investor UncertaintyThe company did not provide 2024 guidance, which creates uncertainty for investors.
Revenue PerformanceRevenue was $2.4 million compared with our estimates of $2.8 million and consensus of $3.2 million.
---
Ownership Overview
0.18%
Insiders
0.68% Mutual Funds
1.61% Other Institutional Investors
97.52% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
NBY FAQ
What was Novabay Pharmaceuticals’s price range in the past 12 months?
Novabay Pharmaceuticals lowest stock price was $0.36 and its highest was $9.11 in the past 12 months.
What is Novabay Pharmaceuticals’s market cap?
Novabay Pharmaceuticals’s market cap is $2.91M.
When is Novabay Pharmaceuticals’s upcoming earnings report date?
Novabay Pharmaceuticals’s upcoming earnings report date is May 08, 2025 which is in 26 days.
How were Novabay Pharmaceuticals’s earnings last quarter?
Novabay Pharmaceuticals released its earnings results on Apr 05, 2025. The company reported -$0.271 earnings per share for the quarter, missing the consensus estimate of -$0.24 by -$0.031.
Is Novabay Pharmaceuticals overvalued?
According to Wall Street analysts Novabay Pharmaceuticals’s price is currently Undervalued.
Does Novabay Pharmaceuticals pay dividends?
Novabay Pharmaceuticals does not currently pay dividends.
What is Novabay Pharmaceuticals’s EPS estimate?
Novabay Pharmaceuticals’s EPS estimate is -0.24.
How many shares outstanding does Novabay Pharmaceuticals have?
Novabay Pharmaceuticals has 5,816,204 shares outstanding.
What happened to Novabay Pharmaceuticals’s price movement after its last earnings report?
Novabay Pharmaceuticals reported an EPS of -$0.271 in its last earnings report, missing expectations of -$0.24. Following the earnings report the stock price went down -1.429%.
Which hedge fund is a major shareholder of Novabay Pharmaceuticals?
Currently, no hedge funds are holding shares in NBY
---
Company Description
Novabay Pharmaceuticals
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
---
NBY Stock 12 Month Forecast
Average Price Target
$0.85
▲(73.47% Upside)
Technical Analysis
RedHill Biopharma
―
Xylo Technologies Ltd
―
Mustang Bio
―
Lixte Biotechnology Holdings
―
Synaptogenix
―
Best Analysts Covering NBY
1 Year
1 Year Success Rate
1/14 ratings generated profit
1 Year Average Return
-65.36%
reiterated a buy rating 5 months ago
Copying Edward Woo's trades and holding each position for 1 Year would result in 7.14% of your transactions generating a profit, with an average return of -65.36% per trade.
---